Inventaire - your friends and communities are your best library

The effect of disease modifying therapies on CD62L expression in multiple sclerosis

author

Margarete Voortman

Michael Khalil

published in: Multiple sclerosis journal - experimental, translational and clinical

date of publication: 2018-07-01

language: English

Cites articles 19

Date

Title

Authors

2017-05-23

Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases

Bob W van Oosten
2017-05-10

The biology of JC polyomavirus

Benedetta Assetta, Walter Atwood
2016-11-04

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Heinz Wiendl, Tilman Schneider-Hohendorf, Nicholas Schwab, Pierre Clavelou
2016-09-21

Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients
2016-08-03

Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis

Lucía Romero Pinel, Alvaro Cobo-Calvo, M A Mañé Martínez, Sergio Martínez Yélamos
2015-12-30

CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients

Richard M Ransohoff
2015-10-12

Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients

Laura Ghezzi, Anne H. Cross
2015-10-02

PML risk stratification using anti-JCV antibody index and L-selectin

Nicholas Schwab, Frauke Zipp, Renaud Du Pasquier, Tilman Schneider-Hohendorf, Dennis Görlich, Volker Siffrin, Xavier Montalban, Christoph Kleinschnitz, Antonio Bertolotto, Heinz Wiendl, Ralf Gold, Felix Luessi, Sven G Meuth, Björn Tackenberg
2015-08-12

Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells

Michela Spadaro, Alessandra Lugaresi, Antonio Bertolotto
2015-06-17

Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients

Sanna Hagman, Laura Airas
2014-03-01

Specific loss of cellular L-selectin on CD4(+) T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection

Nicholas Schwab, Tilman Schneider-Hohendorf, Heinz Wiendl
2013-08-07

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

Nicholas Schwab, Tania Kümpfel, Bernd C Kieseier, Heinz Wiendl, Dorothea Buck, Ralf Gold, Brigitte Wildemann, Sven G Meuth, Christoph Kleinschnitz, Kerstin Göbel
2011-02

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Emmanuelle Waubant, Eva Havrdová, Alan J. Thompson, Massimo Filippi, Michael Hutchinson, Ludwig Kappos, Brian G Weinshenker, Chris Polman, Brenda L Banwell, Stephen C. Reingold, Kazuo Fujihara, Fred D. Lublin, Magnhild Sandberg-Wollheim, Jerry S Wolinsky
2010-03-01

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

Hans-Peter Hartung
2008-10-01

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

Matthias Mehling, Jack P. Antel
2005

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

Hans-Peter Hartung, Massimo Filippi, Ludwig Kappos, Brian G Weinshenker, Chris Polman, Alan J. Thompson, Stephen C. Reingold, Fred D. Lublin, Magnhild Sandberg-Wollheim, Jerry S Wolinsky
2004-03-01

FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors

Johannes Waiser, Klemens Budde, Hans-Hellmut Neumayer, Torsten Böhler
2001-03-01

CD62L is required on effector cells for local interactions in the CNS to cause myelin damage in experimental allergic encephalomyelitis

Richard Flavell, Iqbal S Grewal
1983-11-01

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS),Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)

Article - wd:Q58711606

Welcome to Inventaire

the library of your friends and communities

learn more